Acquisition Details - AstraZeneca has successfully completed the acquisition of Fusion Pharmaceuticals Inc through a statutory plan of arrangement under section 192 of the Canada Business Corporations Act [1] - The acquisition includes all of Fusion's issued and outstanding shares, making Fusion a wholly owned subsidiary of AstraZeneca [3] - Fusion shares will be delisted from the Nasdaq Stock Market and deregistered under the U S Securities Exchange Act of 1934 [3] Financial Terms - AstraZeneca paid $21 00 per share in cash at closing plus a non-transferable contingent value right of $3 00 per share, payable upon achieving a specified regulatory milestone by August 31, 2029 [4] - The total transaction value, including the upfront payment and maximum potential contingent value payment, is approximately $2 4 billion [4] - AstraZeneca also acquired Fusion's cash, cash equivalents, and short-term investments totaling $211 million as of March 31, 2024 [4] Strategic Impact - The acquisition enhances AstraZeneca's oncology portfolio with Fusion's pipeline of radioconjugates (RCs), including the advanced program FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC) [2] - AstraZeneca gains new expertise and capabilities in actinium-based RCs, along with R&D, manufacturing, and supply chain advancements [2] - The deal strengthens AstraZeneca's presence and commitment to Canada [2] Fusion's Pipeline and Capabilities - Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation RCs, which connect alpha particle emitting isotopes to targeting molecules for selective tumor delivery [6] - Fusion's lead program, FPI-2265, targets PSMA for mCRPC and is currently in a Phase II trial [12] - The company operates a state-of-the-art radiopharmaceutical manufacturing facility compliant with Good Manufacturing Practice (GMP) standards [6] Radioconjugates in Oncology - RCs combine precise targeting mechanisms with potent medical radioisotopes to deliver radiation directly to cancer cells, improving efficacy while minimizing toxicity to healthy cells [11] - RCs are administered systemically, enabling their use in tumor types not accessible to external beam radiation and targeting cancer cells that have spread from the primary tumor [11] About FPI-2265 - FPI-2265 is an actinium-225 based PSMA-targeting RC for mCRPC, leveraging alpha particle emissions for more potent cancer cell killing with minimal damage to surrounding healthy tissue [12]

Forward Looking Information To the extent any statements made in this communication contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under Canadian securities law (collectively, "forward-looking statements"). Certain statements in this communication may constitute forward-looking s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) (S ...

Corporate Update Exhibit 99.1 Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for total transaction value of up to $2.4 billion; transaction expected to close in the second quarter of 2024 HAMILTON, ON and BOSTON, MA May 7, 2024 /PRNewswire/ -- Fusion Pharm ...

We expect Fusion Pharmaceuticals (FUSN) to beat expectations when it reports first-quarter 2024 results. Without a marketed product, investors will focus on the upcoming earnings call for updates regarding Fusion’s pipeline candidates.In March 2024, Fusion signed a definitive agreement with AstraZeneca (AZN) , where the latter will acquire all outstanding shares of FUSN for $21 per share in cash, aggregating to $2 billion.The transaction is expected to close in the second quarter of 2024, subject to customa ...

HAMILTON, ON and BOSTON, April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the "Circular") and related materials for the special meeting (the "Meeting") of Fusion's shareholders (the "Shareholders") to approve the previously announced arrangemen ...

In the latest trading session, Fusion Pharmaceuticals Inc. (FUSN) closed at $21.42, marking a +0.63% move from the previous day. This change lagged the S&P 500's 1.2% gain on the day. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 1.59%.Shares of the company witnessed a gain of 0.66% over the previous month, beating the performance of the Medical sector with its loss of 5.82% and the S&P 500's loss of 4.16%.Market participants will be closely following ...

Fusion Pharmaceuticals Inc. (FUSN) closed the most recent trading day at $21.36, making no change from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.The the stock of company has risen by 124.84% in the past month, leading the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.The investment community will be paying close attention to the earnings performance of Fusion Pharmac ...

Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior lutetium-based radioconjugates HAMILTON, ON and BOSTON, April 9, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the presentation of interim efficacy and safety data from t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39344 Fusion Pharmaceuticals Inc. (Exact name of Registrant as specified in its Charter) Canada Not Applicable (State or other jurisd ...